Lighthouse Financial LLC Increases Stock Position in Eli Lilly and Company $LLY

Lighthouse Financial LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.5% in the second quarter, Holdings Channel reports. The fund owned 4,509 shares of the company’s stock after acquiring an additional 110 shares during the quarter. Eli Lilly and Company accounts for about 2.7% of Lighthouse Financial LLC’s portfolio, making the stock its 8th largest position. Lighthouse Financial LLC’s holdings in Eli Lilly and Company were worth $3,515,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of LLY. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter valued at approximately $27,000. Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company in the second quarter valued at $31,000. Blume Capital Management Inc. raised its stake in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the period. IMG Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $35,000. Finally, TD Capital Management LLC lifted its position in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.2%

Shares of LLY opened at $1,023.32 on Tuesday. The business’s 50-day moving average price is $832.59 and its 200-day moving average price is $780.91. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,033.62. The stock has a market cap of $967.43 billion, a PE ratio of 66.88, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. During the same period last year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is 29.35%.

Wall Street Analyst Weigh In

LLY has been the subject of several recent research reports. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. cut their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $886.00 to $1,104.00 in a research report on Monday, November 10th. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $1,015.11.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.